CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage ...

First approved in 2020, first-in-class microtubule inhibitor Klisyri (tirbanibulin 1%) reached the market in early 2021, joining a short list of therapies in the US that are available for AK ...

The Company also presents preclinical combination data of azenosertib with microtubule inhibitor-based antibody drug ...

These results implicate HDAC6, and possibly SIRT2, modalities as therapeutic targets for diseases exhibiting impaired microtubule transport. The effects of HDAC6 and SIRT2 inhibitors on ...

a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer ...

A recent patent from Korea University Research & Business Foundation Sejong Campus describes quinazoline-benzimidazole derivatives acting as microtubule destabilizers (tubulin polymerization ...

ADRX-0134 is a preclinical NaPi2b ADC incorporating AP052, the same clinically validated microtubule inhibitor payload used in Adcentrx's lead program, ADRX-0706 (Nectin-4 ADC), currently ...

Tau hyperphosphorylation contributes to microtubule destabilization and ... targeting of aberrant tau phosphorylation with kinase inhibitors may be feasible. At present no inhibitors are available ...

Eribulin is a microtubule-dynamics inhibitor, structurally modified analogue of halichondrin B, originally isolated from the marine sponge Halichondria okadai. Its mode of action is distinct from ...